To view the PDF file, sign up for a MySharenet subscription.

AFROCENTRIC INVESTMENT CORPORATION LIMITED - Summarised results for the six months ended 31 December 2024

Release Date: 03/03/2025 10:30
Code(s): ACT     PDF:  
Wrap Text
Summarised results for the six months ended 31 December 2024

AfroCentric Investment Corporation Limited
(Incorporated in the Republic of South Africa)
(Registration number 1988/000570/06)
JSE Code: ACT ISIN: ZAE000078416
("AfroCentric" or "the Company")


Summarised results for the six months ended 31 December 2024

Introduction to the AfroCentric Group

AfroCentric is a BEE Level 1, JSE Limited listed investment holding company, which owns and operates
a diverse range of healthcare-related enterprises that provide specialised medical scheme administration
services and deliver a range of healthcare products and services to the public and private healthcare
sectors. The principal objective of the Group is to ensure the delivery of efficient health management
services and the distribution of quality products - all at a manageable and affordable cost for the benefit of
our stakeholders. AfroCentric has successfully broadened its interests in the industry by continuing to
pursue new opportunities to expand and rationalise its presence across the healthcare sector.

On 1 November 2024, the Company announced on SENS that it has changed its financial year-end from
30 June to 31 December, with effect from 31 December 2024. The comparative figures presented are in
respect of the year ended 30 June 2024 and as such may not be comparable to the current reporting
period.

The Board presents a summary of the Company's results for the six months ended 31 December 2024.

Salient Features
                                                            %       Six months ended           Year ended
                                                        change      31 December 2024         30 June 2024


Total revenue from contracts with customers (R'           (51.8)             4 240.9              8 794.7
million)
(Loss)/Profit before tax (R' million)                    (127.0)             (55.79)               206.98
(Loss)/Profit for the period (R' million)                (260.4)            (119.15)                74.26
Basic (loss)/earnings (R' million)                       (327.3)            (125.87)                55.38
Headline earnings (R' million)                            (90.5)               31.93               334.81
Basic (loss)/earnings (cents per share)                  (324.3)             (14.96)                 6.67
Headline earnings (cents per share)                       (90.6)                3.80                40.32
Weighted average number of ordinary shares                            841.09 million       830.33 million
Dividend declared (cents per share)                                                6                   11

Dividends

The Board is pleased to announce that a final gross dividend of 6 cents per ordinary share, has been
declared for the period ended 31 December 2024. Dividends are subject to Dividends Withholding Tax.
The payment date for the dividend is Monday, 12 May 2025.

•      Dividends have been declared out of profits available for distribution.
•      South African Dividends Withholding Tax rate is 20%.
•      The gross dividend amount is 6.00000 cents per ordinary share.
•      Net cash dividend amount is therefore 4.80000 cents per ordinary share.
•      The Company has 841 088 241 ordinary shares in issue as at the declaration date.
•      The Company's income tax reference number is 9600148713
The salient dates relating to the dividend are as follows:

Last day to trade cum dividend                               Tuesday, 6 May 2025
Shares commence trading ex-dividend                          Wednesday, 7 May 2025
Dividend record date                                         Friday, 09 May 2025
Dividend payment date                                        Monday, 12 May 2025

Share certificates for ordinary shares may not be dematerialised or materialised between Wednesday, 7
May 2025 and Friday, 9 May 2025, both days inclusive.

Full Announcement

This short-form announcement is the responsibility of the Directors of the Company and is a summary of
the information contained in the summarised results for the six months ended 31 December 2024 which
were released on 3 March 2025 and can be found on the Company's website
(http://www.afrocentric.za.com/inv-reporting.php).

The financial statements for the six months ended 31 December 2024 were released on SENS on 3 March
2025 and are available for viewing on the following websites:

Company's website: http://www.afrocentric.za.com/inv-reporting.php.

JSE website: https://senspdf.jse.co.za/documents/2025/JSE/ISSE/ACT/Dec2024.pdf.


Management will host a virtual investor presentation tomorrow Tuesday, 04 March 2025 at 10:00 SAST.
The webcast will be accessible at https://www.acannual2024.co.za.

This short-form announcement does not contain full or complete details and any investment decision by
investors and/or shareholders should be based on consideration of the information contained in the
summarised results for the six months ended 31 December 2024, copies of which are also available for
inspection at the Company's offices on workdays during business hours (at no charge) or on request from the
company secretary by email: lebohang.mpumlwana@afrocentrichealth.com


On behalf of the Board




Dr ATM Mokgokong                                             Mr GN van Wyk
Chairman                                                     Group Chief Executive Officer

Johannesburg
3 March 2025


JSE Sponsor to AfroCentric
Questco Corporate Advisory Proprietary Limited

Date: 03-03-2025 10:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.